State Key Laboratory of Bioelectronics, School of Biological Sciences and Medical Engineering, Southeast University, 2 Sipailou, Nanjing, 210096, Jiangsu, China.
Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, CA, 92521, USA.
Mol Cancer. 2020 Nov 12;19(1):159. doi: 10.1186/s12943-020-01280-9.
One unmet challenge in lung cancer diagnosis is to accurately differentiate lung cancer from other lung diseases with similar clinical symptoms and radiological features, such as pulmonary tuberculosis (TB). To identify reliable biomarkers for lung cancer screening, we leverage the recently discovered non-canonical small non-coding RNAs (i.e., tRNA-derived small RNAs [tsRNAs], rRNA-derived small RNAs [rsRNAs], and YRNA-derived small RNAs [ysRNAs]) in human peripheral blood mononuclear cells and develop a molecular signature composed of distinct ts/rs/ysRNAs (TRY-RNA). Our TRY-RNA signature precisely discriminates between control, lung cancer, and pulmonary TB subjects in both the discovery and validation cohorts and outperforms microRNA-based biomarkers, which bears the diagnostic potential for lung cancer screening.
在肺癌诊断中，一个未满足的挑战是如何准确地区分肺癌与其他具有相似临床症状和影像学特征的肺部疾病，如肺结核（TB）。为了确定肺癌筛查的可靠生物标志物，我们利用最近在人外周血单核细胞中发现的非经典小非编码 RNA（即 tRNA 衍生的小 RNA [tsRNAs]、rRNA 衍生的小 RNA [rsRNAs]和 YRNA 衍生的小 RNA [ysRNAs]），开发了一种由不同的 ts/rs/ysRNAs（TRY-RNA）组成的分子特征。我们的 TRY-RNA 特征在发现和验证队列中精确地区分了对照组、肺癌和肺结核患者，并且优于基于 microRNA 的生物标志物，具有肺癌筛查的诊断潜力。
